Collegium Pharmaceutical

COLL

Market cap $1.12B

STOUGHTON, Mass., April 08, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that its management will participate in the following investor conferences: 25th Annual Needham Virtual Healthcare Conference Fireside Chat Date and Time: Wednesday, April 15, 2026, at 2:15 p.m.

6,224 shares were sold for a transaction value of ~$228,000 on March 9, 2026. This sale represented 6.40% of Dieter David's direct holdings prior to the transaction.

Scott Dreyer sold 49,976 shares on March 3, 2026, for approximately $2.02 million at a weighted average price of about $40.41 per share. The sale reduced Dreyer's direct holdings by 41.05%, from 121,746 shares to 71,770 shares.

Collegium Pharmaceutical, Inc. (COLL) Discusses Acquisition of AZSTARYS to Expand ADHD Portfolio and Accelerate Growth Transcript

– Adds Highly Complementary and Differentiated Medicine with Significant Growth Potential to Collegium's Existing ADHD Portfolio – – Enables Greater Impact Across ADHD Patient Communities – – AZSTARYS Expected to Generate Over $50 Million in Second Half 2026 Pro Forma Net Revenue – – Expected Patent Protection into 2037 – – Transaction Expected to be Immediately Accretive to Adjusted EBITDA – – Acquisition to Be Funded by Collegium's Cash on Hand and Previously Announced $300 Million Delayed Draw Term Loan – – Conference Call Scheduled for Today at 9:00 a.m. ET – STOUGHTON, Mass.

Collegium Pharmaceutical, Inc. (COLL) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

STOUGHTON, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it will present two posters featuring real-world data from its portfolio of differentiated pain medications at PainConnect 2026, the American Academy of Pain Medicine (AAPM)'s Annual Meeting, taking place in Salt Lake City, Utah from March 5-8, 2026. The presentations highlight real-world clinical insights from Collegium's pain portfolio and reflect the Company's continued focus on generating evidence that helps inform everyday practice.

STOUGHTON, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that its management will participate in the following investor conferences: Leerink Partners Global Healthcare Conference Monday, March 9, 2026Miami, FL Jefferies Biotech on the Beach Summit Tuesday, March 10, 2026Miami, FL The Citizens Life Sciences Conference Tuesday, March 10, 2026Miami, FL Barclays 28th Annual Global Healthcare Conference Fireside Chat Date and Time: Wednesday, March 11, 2026 at 9:00 a.m.

Collegium Pharmaceutical, Inc. (COLL) Q4 2025 Earnings Call Transcript

Although the revenue and EPS for Collegium Pharmaceutical (COLL) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.